TP53 and bladder transitional cell carcinoma: As was showed in Figure 13 and Table 2, TWS119 had a significant increased sensitivity in TP53 mutation (P = 5.95e-06) of BLCA patients and the IC50 of TWS119 was significant decreased in TP53 mutation group (P < 0.001).